Literature DB >> 31373602

Myocardial MMP-2 contributes to SERCA2a proteolysis during cardiac ischaemia-reperfusion injury.

Andrej Roczkowsky1,2, Brandon Y H Chan1,2, Tim Y T Lee1,2, Zabed Mahmud3, Bridgette Hartley3, Olivier Julien3, Gareth Armanious3, Howard S Young3, Richard Schulz1,2.   

Abstract

AIMS: Matrix metalloproteinase-2 (MMP-2) is a zinc-dependent protease which contributes to cardiac contractile dysfunction when activated during myocardial ischaemia-reperfusion (IR) injury. MMP-2 is localized to several subcellular sites inside cardiac myocytes; however, its role in the sarcoplasmic reticulum (SR) is unknown. The Ca2+ ATPase SERCA2a, which pumps cytosolic Ca2+ into the SR to facilitate muscle relaxation, is degraded in cardiac IR injury; however, the protease responsible for this is unclear. We hypothesized that MMP-2 contributes to cardiac contractile dysfunction by proteolyzing SERCA2a, thereby impairing its activity in IR injury. METHODS AND
RESULTS: Isolated rat hearts were subjected to IR injury in the presence or absence of the selective MMP inhibitor ARP-100, or perfused aerobically as a control. Inhibition of MMP activity with ARP-100 significantly improved the recovery of cardiac mechanical function and prevented the increase of a 70 kDa SERCA2a degradation fragment following IR injury, although 110 kDa SERCA2a and phospholamban levels appeared unchanged. Electrophoresis of IR heart samples followed by LC-MS/MS confirmed the presence of a SERCA2a fragment of ∼70 kDa. MMP-2 activity co-purified with SR-enriched microsomes prepared from the isolated rat hearts. Endogenous SERCA2a in SR-enriched microsomes was proteolyzed to ∼70 kDa products when incubated in vitro with exogenous MMP-2. MMP-2 also cleaved purified porcine SERCA2a in vitro. SERCA activity in SR-enriched microsomes was decreased by IR injury; however, this was not prevented with ARP-100.
CONCLUSION: This study shows that MMP-2 activity is found in SR-enriched microsomes from heart muscle and that SERCA2a is proteolyzed by MMP-2. The cardioprotective actions of MMP inhibition in myocardial IR injury may include the prevention of SERCA2a degradation. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Heart; Ischaemia–reperfusion injury; Matrix metalloproteinase-2; Proteolysis; SERCA

Year:  2020        PMID: 31373602     DOI: 10.1093/cvr/cvz207

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  9 in total

Review 1.  Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways.

Authors:  Jie Wang A; Jingjing Zhang; Mengjie Xiao; Shudong Wang; Jie Wang B; Yuanfang Guo; Yufeng Tang; Junlian Gu
Journal:  Cell Mol Life Sci       Date:  2021-01-13       Impact factor: 9.261

2.  MMP2 and MMP9 contribute to lung ischemia-reperfusion injury via promoting pyroptosis in mice.

Authors:  Peng Zhou; Nai-Cheng Song; Zhi-Kun Zheng; Yi-Qing Li; Jin-Song Li
Journal:  BMC Pulm Med       Date:  2022-06-15       Impact factor: 3.320

3.  Identification of metabolic pathways underlying FGF1 and CHIR99021-mediated cardioprotection.

Authors:  Bing Xu; Fan Li; Wenjing Zhang; Yajuan Su; Ling Tang; Pengsheng Li; Jyotsna Joshi; Aaron Yang; Dong Li; Zhao Wang; Shu Wang; Jingwei Xie; Haiwei Gu; Wuqiang Zhu
Journal:  iScience       Date:  2022-05-23

4.  Dimerization of SERCA2a Enhances Transport Rate and Improves Energetic Efficiency in Living Cells.

Authors:  Elisa Bovo; Roman Nikolaienko; Sean R Cleary; Jaroslava Seflova; Daniel Kahn; Seth L Robia; Aleksey V Zima
Journal:  Biophys J       Date:  2020-08-28       Impact factor: 4.033

5.  Deficiency of myostatin protects skeletal muscle cells from ischemia reperfusion injury.

Authors:  Christoph Wallner; Marius Drysch; Mustafa Becerikli; Sonja Verena Schmidt; Stephan Hahn; Johannes Maximilian Wagner; Felix Reinkemeier; Mehran Dadras; Alexander Sogorski; Maxi von Glinski; Marcus Lehnhardt; Björn Behr
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

6.  Matrix Metalloproteinases Repress Hypertrophic Growth in Cardiac Myocytes.

Authors:  Gerhild Euler; Fabian Locquet; Joanna Kociszewska; Yvonne Osygus; Jacqueline Heger; Rolf Schreckenberg; Klaus-Dieter Schlüter; Éva Kenyeres; Tamara Szabados; Péter Bencsik; Péter Ferdinandy; Rainer Schulz
Journal:  Cardiovasc Drugs Ther       Date:  2021-01-05       Impact factor: 3.727

7.  Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer.

Authors:  Hari Vishal Lakhani; Sneha S Pillai; Mishghan Zehra; Benjamin Dao; Maria Tria Tirona; Ellen Thompson; Komal Sodhi
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

8.  FXYD proteins and sodium pump regulatory mechanisms.

Authors:  John Q Yap; Jaroslava Seflova; Ryan Sweazey; Pablo Artigas; Seth L Robia
Journal:  J Gen Physiol       Date:  2021-04-05       Impact factor: 4.086

9.  Cardioprotective Effect of Novel Matrix Metalloproteinase Inhibitors.

Authors:  Kamilla Gömöri; Tamara Szabados; Éva Kenyeres; Judit Pipis; Imre Földesi; Andrea Siska; György Dormán; Péter Ferdinandy; Anikó Görbe; Péter Bencsik
Journal:  Int J Mol Sci       Date:  2020-09-23       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.